ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
IMMUCELL CORP /DE/
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$10.51−0.24 (-2.23%)
Close on Oct 19, 2026
- Market cap
- $96.58M
- P/E (TTM)
- 131.4
- Dividend yield
- –
Immucell statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of In Vitro & In Vivo Diagnostic Substances companies for comparison
Valuation
| Measure | Immucell | Industry median |
|---|---|---|
| Market Cap | $95.45M | $197.05M |
| Enterprise Value | $94.90M | $106.56M |
| PE Ratio | 131.38 | 20.52 |
| PS Ratio | 3.11 | 3.93 |
| PB Ratio | 3.04 | 2.14 |
| P/TBV Ratio | 3.05 | 2.46 |
| P/FCF Ratio | 22.65 | 18.25 |
| P/OCF Ratio | 16.20 | 13.78 |
Enterprise value
| Measure | Immucell | Industry median |
|---|---|---|
| EV / Sales | 3.09 | 2.69 |
| EV / EBITDA | 15.10 | 14.86 |
| EV / EBIT | 24.54 | 19.00 |
| EV / FCF | 22.52 | 21.02 |
Income (trailing twelve months)
| Measure | Immucell | Industry median |
|---|---|---|
| Revenue | $30.68M | $57.94M |
| Gross Profit | $12.37M | $90.47M |
| Operating Income | $3.87M | -$21.44M |
| Pretax Income | $853.61K | -$14.45M |
| Net Income | $787.37K | -$22.46M |
| EBITDA | $6.29M | -$16.91M |
| EPS (Diluted) | $0.08 | -$0.83 |
Margins
| Measure | Immucell | Industry median |
|---|---|---|
| Gross Margin | 40.3% | 52.3% |
| Operating Margin | 12.6% | -44.5% |
| Pretax Margin | 2.78% | -13.0% |
| Profit Margin | 2.57% | -39.2% |
| EBITDA Margin | 20.5% | -31.3% |
| FCF Margin | 13.7% | -8.85% |
Returns
| Measure | Immucell | Industry median |
|---|---|---|
| Return on Equity (ROE) | 2.57% | -53.1% |
| Return on Assets (ROA) | 1.77% | -41.0% |
| Return on Invested Capital (ROIC) | 11.1% | -32.0% |
| Return on Capital Employed (ROCE) | 9.16% | -37.8% |
Growth
| Measure | Immucell | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 8.49% | 6.01% |
| Net Income Growth (YoY) | -55.3% | -37.7% |
| EPS Growth (YoY) | -57.9% | -29.2% |
| FCF Growth (YoY) | 138.9% | 2.34% |
| Revenue Growth (3Y CAGR) | 14.2% | 2.25% |
| Revenue Growth (5Y CAGR) | 12.5% | 6.42% |
Balance sheet
| Measure | Immucell | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $8.86M | $62.42M |
| Total Debt | $8.30M | $120.13M |
| Net Cash (Debt) | $557.32K | $15.68M |
| Net Cash Per Share | $0.06 | $0.65 |
| Equity (Book Value) | $31.37M | $48.79M |
| Book Value Per Share | $3.45 | $1.36 |
| Tangible Book Value | $31.28M | $23.06M |
| Working Capital | $16.64M | $75.77M |
Financial position
| Measure | Immucell | Industry median |
|---|---|---|
| Current Ratio | 4.75 | 3.30 |
| Quick Ratio | 2.65 | 2.39 |
| Debt / Equity | 0.26 | 0.51 |
| Debt / EBITDA | 1.32 | 3.35 |
| Debt / FCF | 1.97 | 5.05 |
| Net Debt / EBITDA | -0.09 | 2.22 |
| Interest Coverage | 8.87 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Immucell | Industry median |
|---|---|---|
| Operating Cash Flow | $5.89M | -$12.35M |
| Capital Expenditures | -$1.68M | -$1.06M |
| Free Cash Flow | $4.21M | -$20.28M |
| FCF Per Share | $0.46 | -$0.41 |
Efficiency
| Measure | Immucell | Industry median |
|---|---|---|
| Asset Turnover | 0.69 | 0.38 |
| Inventory Turnover | 2.11 | 2.67 |
| Revenue Per Employee | $420.21K | $398.96K |
| Profits Per Employee | $10.79K | -$732.08K |
| Employee Count | 73 | 73 |
Dividends and yields
| Measure | Immucell | Industry median |
|---|---|---|
| Earnings Yield | 0.82% | -21.2% |
| FCF Yield | 4.42% | -7.64% |
| Buyback Yield | 0.00% | -0.58% |
| Shareholder Yield | 0.00% | 0.00% |
Shares
| Measure | Immucell | Industry median |
|---|---|---|
| Shares Outstanding | 9,082,200 | 59,128,900 |
| Shares Change (YoY) | 3.44% | 11.1% |
| Shares Change (QoQ) | 0.39% | 0.54% |
| Float | 7,850,110 | 48,744,500 |
| Shares Held by Insiders | 13.6% | 11.8% |
| Shares Held by Institutions | 14.7% | 59.4% |
Taxes
| Measure | Immucell | Industry median |
|---|---|---|
| Income Tax | $66.23K | $91.50K |
| Effective Tax Rate | 7.76% | 20.6% |
Scores
| Measure | Immucell | Industry median |
|---|---|---|
| Graham Number | $2.49 | $17.36 |
| Graham Upside | -76.3% | -45.5% |
| Altman Z-Score | 4.77 | 0.10 |
| Piotroski F-Score | 7 | 4 |
| Beneish M-Score | -3.10 | -2.62 |
Calculated by StockData from Immucell's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.